Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LHBETATAG retinal tumors
Y Piña1, C Decatur1, TG Murray1, SK Houston1, D Gologorsky1, M Cavalcante1, L Cavalcante1, E Hernandez1, M Celdran1, W Feuer1, T Lampidis21Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA; 2Department of Cell Biology and Anatomy, University of...
Guardado en:
Autores principales: | Y Piña, C Decatur, TG Murray, et al |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf117072b98044bdb024218daeab150b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LHBETATAG retinal tumors
por: Piña Y, et al.
Publicado: (2012) -
Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LHBETATAG retinoblastoma tumors
por: Samuel K Houston, et al.
Publicado: (2011) -
Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury
por: Wang Xiaoping, et al.
Publicado: (2016) -
Suppression of Thioacetamide-Induced Hepatic Injury in Rats treatment with Resveratrol: Role of mammalian Target of Rapamycin (mTOR) Cell Signaling
por: Dallak,Mohammad, et al.
Publicado: (2020) -
Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma
por: Carolina Caro-Vegas, et al.
Publicado: (2019)